Profile data is unavailable for this security.
About the company
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
- Revenue in USD (TTM)114.90m
- Net income in USD-21.95m
- Incorporated2018
- Employees140.00
- LocationCentury Therapeutics Inc25 N 38TH STREET, 11TH FLOORPHILADELPHIA 19104United StatesUSA
- Phone+1 (215) 981-4000
- Fax+1 (302) 655-5049
- Websitehttps://www.centurytx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurosense Therapeutics Ltd | 0.00 | -10.21m | 47.98m | 15.00 | -- | 17.99 | -- | -- | -0.5489 | -0.5489 | 0.00 | 0.1112 | 0.00 | -- | -- | 0.00 | -263.14 | -145.64 | -884.37 | -198.79 | -- | -- | -- | -- | -- | -230.28 | 0.00 | -- | -- | -- | -1.02 | -- | -15.59 | -- |
| OpGen Inc | 1.27m | -9.92m | 48.13m | 100.00 | -- | 16.12 | -- | 38.02 | -13.43 | -13.43 | 0.3776 | 0.2966 | 0.1073 | -- | 5.66 | -- | -79.64 | -87.95 | -178.30 | -127.65 | 4.33 | 15.42 | -742.49 | -794.78 | -- | -- | 0.00 | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
| Renovaro Inc | 0.00 | -67.01m | 48.35m | 25.00 | -- | 0.5161 | -- | -- | -0.4327 | -0.4327 | 0.00 | 0.5443 | 0.00 | -- | -- | 0.00 | -40.61 | -39.86 | -47.81 | -42.11 | -- | -- | -- | -- | -- | -10.46 | 0.0634 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
| Kalaris Therapeutics Inc | 0.00 | -38.67m | 48.81m | 6.00 | -- | 0.7642 | -- | -- | -6.24 | -6.24 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -31.28 | -52.59 | -33.27 | -57.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.14 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 0.00 | -45.51m | 48.98m | 37.00 | -- | 1.91 | -- | -- | -1.47 | -1.47 | 0.00 | 0.8236 | 0.00 | -- | -- | 0.00 | -57.98 | -43.20 | -64.18 | -47.84 | -- | -- | -- | -7,408.74 | -- | -- | 0.0007 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| Serina Therapeutics Inc | 65.00k | -939.00k | 51.34m | 12.00 | -- | 30.08 | -- | 789.85 | -0.0516 | -0.0516 | 0.0068 | 0.1713 | 0.0074 | -- | -- | 5,416.67 | -11.53 | -188.54 | -153.87 | -- | -- | -- | -1,560.00 | -7,513.03 | -- | -- | 0.00 | -- | -60.56 | -49.64 | 24.74 | -- | -49.05 | -- |
| Senti Biosciences Inc | 0.00 | -54.79m | 51.38m | 34.00 | -- | 1.35 | -- | -- | -10.30 | -10.30 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -59.25 | -50.97 | -66.56 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Precision BioSciences Inc | 51.14m | -21.99m | 51.45m | 107.00 | -- | 0.9921 | -- | 1.01 | -2.01 | -2.01 | 6.47 | 4.68 | 0.3309 | -- | 58.35 | 473,527.80 | -14.22 | -26.22 | -16.69 | -33.68 | -- | -- | -42.99 | -87.80 | -- | -- | 0.3117 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Century Therapeutics Inc | 114.90m | -21.95m | 51.69m | 140.00 | -- | 0.2149 | -- | 0.4498 | -0.2819 | -0.2819 | 1.36 | 2.79 | 0.346 | -- | -- | 820,707.10 | -6.61 | -33.69 | -6.93 | -36.94 | -- | -- | -19.10 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| Jasper Therapeutics Inc | 0.00 | -78.78m | 52.13m | 64.00 | -- | 1.23 | -- | -- | -5.25 | -5.25 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -85.84 | -75.11 | -97.08 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| Avalo Therapeutics Inc | 441.00k | -21.10m | 53.06m | 23.00 | 0.2236 | 0.4327 | 0.724 | 120.31 | 21.91 | 21.91 | 0.0496 | 11.32 | 0.0034 | -- | -- | 19,173.91 | 55.68 | -94.60 | 356.71 | -128.31 | 164.85 | 81.11 | 16,556.01 | -790.66 | -- | -- | 0.00 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
| Artiva Biotherapeutics Inc | 0.00 | -71.72m | 53.11m | 96.00 | -- | 0.3147 | -- | -- | -3.19 | -3.19 | 0.00 | 6.93 | 0.00 | -- | -- | 0.00 | -50.97 | -44.57 | -55.41 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0008 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Aligos Therapeutics Inc | 3.27m | -53.26m | 53.14m | 70.00 | -- | 0.516 | -- | 16.25 | -10.39 | -10.39 | 0.4751 | 16.84 | 0.0235 | -- | -- | 46,714.29 | -38.23 | -60.83 | -44.24 | -72.31 | -- | -- | -1,628.75 | -1,462.14 | -- | -- | 0.0014 | -- | -74.60 | -- | -49.65 | -- | -45.83 | -- |
| vTv Therapeutics Inc | 17.00k | -18.69m | 53.38m | 23.00 | -- | 6.73 | -- | 3,140.07 | -3.01 | -3.01 | 0.0027 | 2.48 | 0.0004 | -- | -- | 739.13 | -53.13 | -96.30 | -68.57 | -- | -- | -- | -134,723.50 | -775.06 | -- | -- | 0.00 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -19.70m | 53.95m | 13.00 | -- | 10.66 | -- | -- | -0.8202 | -0.8202 | 0.00 | 0.167 | 0.00 | -- | -- | 0.00 | -191.49 | -208.29 | -371.24 | -373.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -17.61 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -20.93m | 54.98m | 23.00 | -- | 9.25 | -- | -- | -0.8868 | -0.8868 | 0.00 | 0.2011 | 0.00 | -- | -- | 0.00 | -159.74 | -79.58 | -258.86 | -95.32 | -- | -- | -- | -19,975.78 | -- | -- | 0.0689 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
Data as of Jul 15 2025. Currency figures normalised to Century Therapeutics Inc's reporting currency: US Dollar USD
20.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Casdin Capital LLCas of 31 Mar 2025 | 3.21m | 3.78% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 2.74m | 3.22% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 2.59m | 3.05% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 2.35m | 2.76% |
| DAFNA Capital Management LLCas of 31 Mar 2025 | 1.70m | 2.00% |
| Syncona Investment Management Ltd.as of 31 Mar 2025 | 1.21m | 1.43% |
| Renaissance Technologies LLCas of 31 Mar 2025 | 1.19m | 1.39% |
| Geode Capital Management LLCas of 31 Mar 2025 | 970.26k | 1.14% |
| Tang Capital Management LLCas of 31 Mar 2025 | 900.00k | 1.06% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 846.22k | 1.00% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
